Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study.
Kudo M, Aoki T, Ueshima K, Tsuchiya K, Morita M, Chishina H, Takita M, Hagiwara S, Minami Y, Ida H, Nishida N, Ogawa C, Tomonari T, Nakamura N, Kuroda H, Takebe A, Takeyama Y, Hidaka M, Eguchi S, Chan SL, Kurosaki M, Izumi N. Kudo M, et al. Among authors: tomonari t. Liver Cancer. 2023 Feb 7;12(4):321-338. doi: 10.1159/000529574. eCollection 2023 Sep. Liver Cancer. 2023. PMID: 37901197 Free PMC article.
Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A Multicenter Study Involving 9,411 Japanese Patients.
Maeda M, Saeki I, Sakaida I, Aikata H, Araki Y, Ogawa C, Kariyama K, Nouso K, Kitamoto M, Kobashi H, Sato S, Shibata H, Joko K, Takaki S, Takabatake H, Tsutsui A, Takaguchi K, Tomonari T, Nakamura S, Nagahara T, Hiraoka A, Matono T, Koda M, Mandai M, Mannami T, Mitsuda A, Moriya T, Yabushita K, Tani J, Yagi T, Yamasaki T. Maeda M, et al. Among authors: tomonari t. Liver Cancer. 2020 Jan;9(1):50-62. doi: 10.1159/000502744. Epub 2019 Oct 22. Liver Cancer. 2020. PMID: 32071909 Free PMC article.
Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis.
Tomonari T, Sato Y, Tani J, Hirose A, Ogawa C, Morishita A, Tanaka H, Tanaka T, Taniguchi T, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Uchida K, Masaki T, Takayama T. Tomonari T, et al. Hepatol Res. 2021 Apr;51(4):472-481. doi: 10.1111/hepr.13597. Epub 2021 Mar 1. Hepatol Res. 2021. PMID: 33238074
Sequential therapy including regorafenib for unresectable hepatocellular carcinoma: Effect of early relative changes in hepatic functional reserve after regorafenib administration on prognosis.
Ochi H, Tani J, Tomonari T, Taniguchi T, Koizumi Y, Hirose A, Ogawa C, Hiraoka A, Morishita A, Moriya A, Hirooka M, Deguchi A, Symple Study Group. Ochi H, et al. Among authors: tomonari t. Hepatol Res. 2021 Dec;51(12):1219-1228. doi: 10.1111/hepr.13713. Epub 2021 Sep 29. Hepatol Res. 2021. PMID: 34534398
Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma.
Tomonari T, Tani J, Ogawa C, Deguchi A, Senoh T, Moriya A, Shibata H, Fukuno H, Tanaka H, Tanaka T, Taniguchi T, Sogabe M, Kawano Y, Morishita A, Takaguchi K, Miyamoto H, Sato Y, Masaki T, Takayama T. Tomonari T, et al. Hepatol Res. 2023 Feb;53(2):172-178. doi: 10.1111/hepr.13845. Epub 2022 Oct 18. Hepatol Res. 2023. PMID: 36214071
Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma.
Imakura T, Sato S, Tomonari T, Murakami K, Takahashi N, Naito N, Mima M, Kagawa K, Koyama K, Nishimura H, Kawano H, Nokihara H, Azuma M, Takayama T, Nishioka Y. Imakura T, et al. Among authors: tomonari t. Intern Med. 2022 Apr 15;61(8):1211-1217. doi: 10.2169/internalmedicine.7300-21. Epub 2021 Sep 18. Intern Med. 2022. PMID: 34544944 Free PMC article.
59 results